Best Life Sciences Companies in Aurora, United States
The 33 best Life Sciences companies in Aurora, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Foresight Diagnostics.
Our analysis of 164 Life Sciences companies
$34.7b in tracked funding; 83% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Life Sciences companies in Aurora
| # | Company | Disclosed funding | Last round | Stage | Employees | Founder | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Foresight Diagnostics Developer of minimally-invasive liquid biopsy test for the detection of cancer | $104M | 27 mo ago | Acquired | 35 | Ash Alizadeh Co-Founder | WordPressApple iCloud MailMySQL+21 | — | — |
| 2 | Cerebral Therapeutics Early-stage drug delivery company developing Intracerebroventricular (ICV) delivery methods for Valproate for… | $86M | 52 mo ago | Series C | 19 | — | — | — | — |
| 3 | Ocugen Developer of therapeutic solutions to treat various eye disorders | $58M | 77 mo ago | Public | 84 84 → 130 (+55%) | — | DrupalPHPAmazon Web Services+21 | 57 patents Patents concentrated in health & consumer products | — |
| 4 | Precision Biopsy Developed system for prostate biopsies & diagnosis of prostate cancer | $41M | 120 mo ago | Deadpooled | 13 | — | — | — | — |
| 5 | Taiga Biotech Cellular therapies for hematological diseases. | $27M | 75 mo ago | Deadpooled | 2 | — | — | — | — |
| 6 | BaroFold Manufacturer of protein therapeutics for immunology indications | $16M | 164 mo ago | Acqui-Hired | 7 | Matt Brewer Co-Founder & CEO | — | 59 patents Protein refolding technologies for therapeutic biologics, reducing aggregation and immunogenicity. | — |
| 7 | OncoVerity Developer of therapeutics for the treatment of cancer | $14M | 23 mo ago | Series A | — | Max Colao CEO | — | — | — |
| 8 | Rock Immune Developer of immunotoxins for cancer therapy | $7M | 20 mo ago | Funding Raised | — | Zhirui Wang Founder | — | — | — |
| 9 | GelSana Developer of novel hydrogels for wound healing | $4M | 15 mo ago | Series A | 2 | Melissa Krebs Founder & CEO | WordPress Block EditorWordPressMySQL+21 | — | — |
| 10 | Sharklet Technologies Pattern Alone Technology to Inhibit Bacterial Contamination used in Medical Applications and Equipment | $3M | 166 mo ago | Series A | 17 | Mark Spiecker ex-CEO | WordPressMySQLPHP+22 | 17 patents Micro‑textured surface engineering for medical devices improving flow, adhesion, and healing | — |
| 11 | Triopsy Developer of medical device for cancer diagnosis | $2M | 33 mo ago | Seed | 5 | David Bostwick CEO | — | — | — |
| 12 | Z biotech Glycomics solutions provider advancing research with innovative glycan microarray technology | $2M | 14 mo ago | Funding Raised | 6 | — | — | 109 patents Patents concentrated in health & consumer products | — |
| 13 | MenoGeniX Developing biopharmaceutical alternative therapies for menopausal vasomotor symptoms | $1M | 77 mo ago | Seed | 3 | Richard Duke CEO & Chairman | — | 9 patents Pharmaceutical compositions treating menopause and hormonal variation symptoms, including G‑CSF formulations. | — |
| 14 | Allander Biotechnologies Developer of tissue regeneration technology for ulcers and wound management | $1M | 37 mo ago | Seed | — | Xiao Wang Founder & President | — | — | — |
| 15 | CariCord Cord blood and placental banking for newborn stem cell therapies | $840K | 103 mo ago | Acqui-Hired | 12 | Calvin Cole President and CEO | — | — | — |
| 16 | Neurexis Therapeutics Developer of therapeutic peptide for neuroprotective effect | $605K | 14 mo ago | Seed | 3 | — | — | — | — |
| 17 | Exxel Pharma Developer of drugs for pain management | $600K | 23 mo ago | Funding Raised | 3 | Soren Mogelsvang CEO & President | — | — | — |
| 18 | Vega Surgical Provider of surgical solutions for cranial neurosurgical disorders | $315K | 27 mo ago | Funding Raised | — | Zach Folzenlogen Co-Founder | — | — | — |
| 19 | Clarimedix Develops products for the treatment of conditions associated with vascular dysfunction | $275K | 184 mo ago | Deadpooled | — | — | — | 12 patents Photobiomodulation devices targeting mitochondrial function for hypoxia‑related disease therapy. | — |
| 20 | Greffex Developer of an adenoviral vector technology platform for vaccine delivery | $155K | 68 mo ago | Early Stage | 14 | John Price President & Chief Executive Officer | — | 52 patents Viral vector gene therapies and universal vaccine antigen design for infectious diseases | — |
Top 12 Life Sciences companies in Aurora
#1
Series A · Aurora, Colorado · founded 2020 · 2 employees$4.2Mraised▾
Developer of novel hydrogels for wound healing. The company has developed the first bio-inert adhesive hydrogel delivery system that offers controlled delivery of therapeutics to promote healing and accelerate wound closure while avoiding unwanted inflammatory responses.
- Jul 2025Grant (prize money)$299.6K
- Sep 2024Grant (prize money)$325K
- Nov 2023Series A$3.5M
- Apr 2023Grant (prize money)$299.6K
#2
Funding Raised · Aurora, Colorado · founded 2013 · 6 employees$2.3Mraised▾
Glycomics solutions provider advancing research with innovative glycan microarray technology. This biotech company specializes in glycan microarray products and services, enabling researchers to gain insights into glycobiology for human health and disease understanding. Leveraging expertise in glycobiology, glycoengineering, and surface chemistry, they offer a range of products including glycan & lectin arrays, glycopeptide microarrays, assay buffers, and glycan-binding reagents. Services encompass glycan microarray analysis, glycosylation analysis, and custom glycan & glycopeptide synthesis. The company's technology supports applications in cancer research, influenza research, and drug discovery. They provide personalized guidance, study design assistance, sample handling recommendations, and data interpretation support. The company is dedicated to innovation, rigor, and quality, providing outstanding solutions and support for biotech, pharmaceutical companies, and leading research institutes. They offer a one-stop glycomics shop, helping to realize the promise of glycobiology research and reveal novel discoveries.
- Aug 2025Grant (prize money)$306.8K
- Aug 2025Grant (prize money)$314K
- Apr 2025Grant (prize money)$1.6M
#3
Funding Raised · Aurora, Colorado · founded 2020$6.7Mraised▾
Developer of immunotoxins for cancer therapy. The company focused on the development and commercialization of diphtheria toxin-based recombinant immunotoxins for treatment of cancer & autoimmune diseases. The company's product include CCR4-IL2 bispecific immunotoxin for Cutaneous T-cell Lymphoma.
- Mar 2025Grant (prize money)$2.4M
- Aug 2022Grant (prize money)$4.3M
#4
Acquired · Aurora, Colorado · founded 2020 · 35 employees$104.2Mraised▾
Developer of minimally-invasive liquid biopsy test for the detection of cancer. The company uses PhasED-Seq technology to develop liquid biopsy testing platform enabling detection of ctDNA levels in patients with solid tumors and hematologic malignancies.
- Jul 2024Series B$33M
- Apr 2023Series B$58.8M
- Jun 2021Series A$12.5M
#5
Series A · Aurora, Colorado · founded 2022$14Mraised▾
Developer of therapeutics for the treatment of cancer. The company is pioneering the use of clinical and single cell multiomics database to advance the development of cusatuzumab, a novel anti-CD70 antibody, for the treatment of acute myeloid leukemia (AML) and other cancers.
- Nov 2024Series A$14M
#6
Seed · Aurora, Colorado · founded 2020 · 3 employees$605Kraised▾
Developer of therapeutic peptide for neuroprotective effect. The company has developed tatCN19o, a 30 amino acid peptide consisting of two functional domains for the drug to cross the blood-brain barrier, and another domain is a Ca2+/calmodulin-dependent protein kinase II (CaMKII)-specific inhibitor.
- Aug 2025Grant (prize money)$2.8M
- Apr 2025Grant (prize money)$898.6K
- Sep 2024Grant (prize money)$3M
- May 2022Seed$55K
#7
Series C · Aurora, Colorado · founded 2010 · 19 employees$85.8Mraised▾
Cerebral Therapeutics is developing Intracerebroventricular (ICV) delivery methods for Valproate for the treatment of neurological diseases such as epilepsy. In Oct.2015, Cerebral therapeutics signed an exclusive agreement with Flowonix Medical to develop the implanted drug delivery system which provides the infusion of therapeutic drugs directly to targeted areas of the brain. The implants will deliver micro-dosages of the small molecule drug. This addresses several issues with current oral formulations for epilepsy, including crossing the blood-brain barrier, bioavailability, side effects and patient adherence to the drug. Early clinical trials were started in Aug.2016 (study ref: NCT02899611)
- Jun 2022Series C$40M
- Jan 2020Series B$35M
- Mar 2019Series A$7.8M
- Jun 2018Series A$3M
#8
Funding Raised · Aurora, Colorado · founded 2017 · 3 employees$600Kraised▾
Exxel Pharma is a developer of drugs for pain management. It has developed innovative, small molecule-based medicines for the management of pain, PTSD and use disorders. It uses small molecule therapeutics technology and the endocannabinoid system for the development of drugs. It has developed URB937 drugs that provide solutions for the treatment of chronic neuropathic pain. It is a small molecule, a peripheral inhibitor of the enzyme fatty acid amide hydrolase enzyme that breaks down the naturally occurring endocannabinoid anandamide, and inhibition of FAAH by URB937 resulting in elevated anandamide levels. Other products include URB597 that prevents degradation of the endocannabinoid anandamide and leading to increased cannabinoid receptor signaling.
- Nov 2024Conventional Debt$600K
#9
Public · Aurora, Colorado · founded 2013 · 84 employees$58.3Mraised▾
Developer of therapeutic solutions to treat various eye disorders. The company is developing protein therapeutics for eye diseases including ocular graft versus host disease, retinitis pigmentosa, geographic atrophy, wet age-related macular degeneration, and diabetic retinopathy. The products include OCU400 for associated retinal degeneration, OCU410 for dry age-related macular degeneration, and OCU 200 for diabetic macular Edema and Retinopathy.
- May 2020Post IPO$14.3M
- Aug 2019Post IPO$25M
- Nov 2018Post IPO$350.4K
- Feb 2018Post IPO$5M
#10
Seed · Aurora, Colorado · founded 2012 · 5 employees$2.4Mraised▾
Developer of medical device for cancer diagnosis. The company has developed a comprehensive system based on novel biopsy and pathology technology to the precise tumor location, disease type and stage, genomic analysis, and pathway to personalized medicine. It aid in the diagnosis and treatment planning of prostate cancer in men.
- Jan 2024Seed$100K
- Mar 2023Seed$1.5M
- May 2022Seed$250K
- Aug 2018Seed$850K
#11
Deadpooled · Aurora, Colorado · founded 2006 · 2 employees$26.9Mraised▾
Taiga Biotechnologies develops cellular therapeutics for hematological diseases. Its proprietary platform technology uses conditionally immortalized adult hematopoetic stem cells (HSCs). The company is pursuing indications in cancer and infectious diseases. In addition, Taiga is also investigating a protein biologic that improves outcomes after bone marrow transplants, processes for stem-cell based alternatives to blood transfusions and other immunotherapies.
- Jul 2020Conventional Debt$14M
- Jun 2019Series B$3M
- Mar 2018Series B$8.7M
- Sep 2014Grant (prize money)$186.3K
#12
Deadpooled · Aurora, Colorado · founded 2008 · 13 employees$41.1Mraised▾
Precision Biopsy was formed in partnership with Allied Minds to develop and commercialize novel technology for the diagnosis of prostate cancer. The company’s diagnostic technology uses advanced spectroscopy imaging techniques in combination with tissue biopsy. Precision Biopsy is a subsidiary of Allied Minds.
- Oct 2016Series B$5M
- Oct 2015Series B$33.6M
- Jul 2011Series A$2.5M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Life Sciences coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.